Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sichuan Hebang Group Industry is a prominent Chinese industrial conglomerate primarily recognized for its dominant position in the chemical and agrochemical industries. Operating largely through its subsidiary, Sichuan Hebang Biotechnology, the company is a leading global producer of soda ash, ammonium chloride, and the herbicide glyphosate. While its core business is industrial, the group maintains a presence in the life sciences sector through the production of animal nutrition additives like methionine and a pharmaceutical division that manufactures active pharmaceutical ingredients (APIs). Its pharmaceutical portfolio includes generic treatments for metabolic disorders, such as metformin and gliclazide. Additionally, the company has significantly expanded into the renewable energy sector, focusing on the production of high-purity solar-grade silicon and photovoltaic glass.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sichuan Hebang Group Industry.